David E Dawe
Overview
Explore the profile of David E Dawe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Biggs K, Ouellette-Kuntz H, Griffiths R, Hansford R, Hallet J, Kelly C, et al.
Cancer Med
. 2025 Jan;
14(1):e70579.
PMID: 39778071
Background: Adults with intellectual or developmental disability (IDD) are at higher risk for incomplete cancer staging. Aim: To compare unknown stage data between those with and without IDD. Materials And...
2.
Meyers D, Rittberg R, Dawe D, Banerji S
Curr Oncol
. 2024 Sep;
31(9):5498-5515.
PMID: 39330035
Since the initial US FDA approval of an immune checkpoint inhibitor (ICI) for the treatment of non-oncogene-driven non-small-cell lung cancer (NSCLC) nine years ago, this therapeutic strategy has been cemented...
3.
Piccirillo M, Chu Q, Bradbury P, Tu W, Coschi C, Grosso F, et al.
J Thorac Oncol
. 2024 Aug;
19(11):1578-1579.
PMID: 39186030
No abstract available.
4.
Hajj-Boutros G, Faust A, Muscedere J, Kim P, Abumrad N, Chevalier S, et al.
J Gerontol A Biol Sci Med Sci
. 2024 Mar;
79(7).
PMID: 38486371
The inaugural Canadian Conferences on Translational Geroscience were held as 2 complementary sessions in October and November 2023. The conferences explored the profound interplay between the biology of aging, social...
5.
Hansford R, Ouellette-Kuntz H, Griffiths R, Hallet J, Decker K, Dawe D, et al.
Can J Public Health
. 2024 Feb;
115(2):332-342.
PMID: 38315327
Objectives: Cancer is a leading cause of death among people living with intellectual or developmental disabilities (IDD). There is little empirical evidence documenting survival or comparing outcomes to those without...
6.
Rittberg R, Decker K, Lambert P, Bravo J, St John P, Turner D, et al.
J Geriatr Oncol
. 2024 Jan;
15(2):101689.
PMID: 38219331
Introduction: Cancer incidence, comorbidity, and polypharmacy increase with age, but the interplay between these factors on receipt of systemic therapy (ST) in advanced cancer has rarely been studied. Materials And...
7.
Dawe D, Rittberg R, Syed I, Shanahan M, Moldaver D, Bucher O, et al.
Front Oncol
. 2023 Dec;
13:1191920.
PMID: 38125937
Background: Although therapy for limited-stage small-cell lung cancer (LS-SCLC) is administered with curative intent, most patients relapse and eventually die of recurrent disease. Chemotherapy (CT) with concurrent radiotherapy (RT) remains...
8.
Hansford R, Ouellette-Kuntz H, Bourque M, Decker K, Derksen S, Hallet J, et al.
Cancer Epidemiol
. 2023 Nov;
88:102500.
PMID: 38035452
Background: Cancer is a leading cause of death among adults living with intellectual or developmental disabilities (IDD). However, few epidemiological studies exist worldwide quantifying inequalities in cancer stage at diagnosis...
9.
Chu Q, Perrone F, Greillier L, Tu W, Piccirillo M, Grosso F, et al.
Lancet
. 2023 Nov;
402(10419):2295-2306.
PMID: 37931632
Background: Pleural mesothelioma usually presents at an advanced, incurable stage. Chemotherapy with platinum-pemetrexed is a standard treatment. We hypothesised that the addition of pembrolizumab to platinum-pemetrexed would improve overall survival...
10.
Mahar A, Biggs K, Hansford R, Derksen S, Griffiths R, Enns J, et al.
Cancer
. 2023 Oct;
130(5):740-749.
PMID: 37902956
Background: Cancer is a leading cause of death among people living with intellectual or developmental disabilities (IDD). Although studies have documented lower cancer screening rates, there is limited epidemiological evidence...